78106

Identification of genetic profile associated with response to treatment with protein Smoothened (SMO) inhibitors in paediatric medulloblastoma patients

Favoritar este trabalho

Medulloblastoma is the most common malignant brain tumor in children. Recent reports have shown that this tumor is not a single disease, but comprises at least four subgroups, named Wingless, Sonic-Hedgehog, group 3 and group 4, each with its particular molecular profile and clinical features. Although current treatment protocols lead to 70-85% survival rate, there are many neurological side effects due the therapy. For those pacients with medulloblastoma of Sonic-Hedgehog subgroup, an option using Smoothened inhibitors has been considered to target Sonic-Hedgehog pathway. However, primary and acquired resistance to the treatment with these inhibitors are a limiting factor for its clinical use. The present study aims to identify mutations in Sonic-Hedgehog pathway genes on tumor samples of medulloblastoma to identify genetic profiles predictive of the response to Smoothened inhibitors as well assess whether formalin-fixed paraffin embedded samples are suitable for this type of genetic analysis. Furthermore, we intend to estabilish if there is a correlation between tumoral genetic profile and clinical progression of disease.